文献速递产科母胎医学

孕前使用胰高血糖素样肽-1受体激动剂与不良产科结局风险降低相关

Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes.
PubMed 文献 · Am J Obstet Gynecol · 2025-01-21

基于美国TriNetX协作网络的回顾性队列研究,匹配后各4267例,孕前2年内使用胰高血糖素样肽-1受体激动剂者妊娠期糖尿病、妊娠期高血压疾病、早产及剖宫产的风险均低于未使用组,但需未来研究明确该类药物如何最佳融入孕前健康优化。

要点

  • 孕前2年内使用胰高血糖素样肽-1受体激动剂与妊娠期糖尿病风险降低相关(OR 0.81)。
  • 孕前使用与妊娠期高血压疾病风险降低相关(OR 0.84)。
  • 孕前使用与早产(OR 0.68)及剖宫产(OR 0.89)风险降低相关。

核心结论

  • 孕前24个月内处方胰高血糖素样肽-1受体激动剂与多种不良产科结局风险降低相关,包括妊娠期糖尿病、妊娠期高血压疾病、早产和剖宫产。
  • 作者认为,胰高血糖素样肽-1受体激动剂的使用可能是改善高危人群围产期结局的有力工具,但未来研究需要明确该类药物如何最佳融入孕前健康优化。

研究设计与样本

  • 回顾性队列研究,使用美国TriNetX协作网络,纳入年龄≥18岁的女性患者。
  • 暴露组为妊娠前2年内接受胰高血糖素样肽-1受体激动剂处方的个体;未暴露组为有妊娠史但无既往胰高血糖素样肽-1受体激动剂使用史的个体。
  • 队列按年龄、种族、族裔和合并症病史进行匹配,匹配后每组各4267人。

主要发现

  • 妊娠期糖尿病发生率:未使用组18.2% vs 使用组15.2%,OR 0.81(95%CI 0.72-0.91)。
  • 妊娠期高血压疾病发生率:未使用组22.8% vs 使用组19.9%,OR 0.84(95%CI 0.76-0.94)。
  • 早产发生率:未使用组4.4% vs 使用组3.0%,OR 0.68(95%CI 0.54-0.85)。
  • 剖宫产发生率:未使用组19.7% vs 使用组17.6%,OR 0.89(95%CI 0.87-0.97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of glucagon-like peptide-1 receptor agonists has greatly increased in patients of reproductive age within the past 4 years. However, there is limited research on the long-term effects of these medications on future pregnancies. OBJECTIVE: This study aimed to evaluate the association between adverse obstetrical outcomes and antecedent glucagon-like peptide-1 receptor agonist use using a nationally representative database. STUDY DESIGN: This was a retrospective cohort study of female patients aged ≥18 years using the US Collaborative Network in TriNetX. The exposure cohort was composed of individuals who received a glucagon-like peptide-1 receptor agonist prescription within the 2 years preceding pregnancy. The unexposed cohort was composed of individuals with a history of pregnancy but no previous history of glucagon-like peptide-1 receptor agonist use. The cohorts were matched for age, race, ethnicity, and history of comorbid conditions. The International Classification of Diseases, Tenth Revision, codes for hypertensive disorders of pregnancy, gestational diabetes mellitus, preterm delivery, and rates of cesarean delivery were the primary outcomes of interest compared between the cohorts. Logistic regression was performed using TriNetX to determine the odds ratios and 95% confidence intervals. RESULTS: After matching, there were 4267 individuals in each cohort. Compared with individuals who had no prescription for glucagon-like peptide-1 receptor agonist, those who had a prescription for glucagon-like peptide-1 receptor agonist were less likely to develop gestational diabetes mellitus (18.2% vs 15.2%, respectively; odds ratio, 0.81; 95% confidence interval, 0.72-0.91) and hypertensive disorders of pregnancy (22.8% vs 19.9%, respectively; odds ratio, 0.84; 95% confidence interval, 0.76-0.94), experience preterm delivery (4.4% vs 3.0%, respectively; odds ratio, 0.68; 95% confidence interval, 0.54-0.85), and undergo cesarean delivery (19.7% vs 17.6%, respectively; odds ratio, 0.89; 95% confidence interval, 0.87-0.97). CONCLUSION: The prescription of glucagon-like peptide-1 receptor agonist within 24 months preceding a pregnancy was associated with a reduced risk of several adverse obstetrical outcomes, including gestational diabetes mellitus, hypertensive disorders of pregnancy, preterm delivery, and cesarean delivery. This suggests that the use of glucagon-like peptide-1 receptor agonists may be a powerful tool to improve perinatal outcomes in high-risk populations. However, future research is needed to define how this class of medication is best incorporated clinically into preconception health optimization.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Imbroane MR, LeMoine F, Nau CT, et al. Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes. Am J Obstet Gynecol. 2025. PMID: 39848396. doi:10.1016/j.ajog.2025.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。